ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0166

Effect of Air Pollution on Prevalence and Disease Activity of Rheumatoid Arthritis in the German Middle-aged Population from the NAKO Baseline Examination
Abstract Number: 0063

Effect of alpha-ketoglutarate on Synovial Fibroblasts-Mediated Inflammation in Arthritis
Abstract Number: 2498

Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Abstract Number: 1371

Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Abstract Number: 2440

Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study
Abstract Number: 0590

Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Abstract Number: 2694

Effect of Deucravacitinib Treatment on Renal Dysfunction–Associated Plasma Biomarkers From a Phase 2 Study in Patients With Systemic Lupus Erythematosus
Abstract Number: 2671

Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Abstract Number: 1191

Effect of ER Stress Inhibition With 4-Phenylbutyric Acid on Disease Phenotype in a Mouse Model of Myositis
Abstract Number: 0596

Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Abstract Number: 1460

Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Abstract Number: 2618

Effect of Implementing a Dashboard with or without a Best Practice Alert on HLA-B*58:01 Testing Rates among Allopurinol Users at VA Medical Centers
Abstract Number: 1354

Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Abstract Number: 1373

Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Abstract Number: 0095

Effect of JAK Inhibitors on Osteoblast Differentiation

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].